Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOGEN INC.

Get SEC filing alerts via email and in your feed for BIOGEN INC.

BIIB

BIOGEN INC.

About BIOGEN INC.

Biogen Inc. is a global biopharmaceutical company specializing in discovering, developing, and delivering therapies for serious neurological, immunological, and rare diseases. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and Friedreich’s ataxia. Biogen also commercializes biosimilars and collaborates with partners to advance innovative medicines, leveraging extensive R&D, patent protection, and global marketing to serve patients and healthcare providers worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BIOGEN INC.

1
1
BIOGEN INC. Biogen Reports $2.48 Billion Revenue in Q1 2026, Net Income Rises to $319.5 Million

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BIOGEN INC. Biogen Reports $9.89 Billion Revenue with Decrease in Net Income for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
BIOGEN INC. Biogen Reports $2.53 Billion Revenue in Q3 2025, Driven by VUMERITY and SKYCLARYS Sales

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIOGEN INC. Biogen Reports $2.645 Billion Revenue in Q2 2025, Net Income Rises to $634.8 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIOGEN INC. Biogen Reports $2.43 Billion Revenue in Q1 2025, Net Income Declines to $240.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BIOGEN INC. Biogen Reports $9.7 Billion Revenue in 2024, Earnings Per Share Increase by 40.3%

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
BIOGEN INC. Biogen Reports 2.5% Revenue Decline, Net Income Recovery in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments